An Analysis of the Diagnostic Performance of Tc-99m PSMA SSPECT/CT in Biochemically Recurrent Prostate Cancer Compared with Ga-68 PSMA PET/CT: A Single-center, Prospective Study

被引:1
作者
Ora, Manish [1 ]
Saini, Vivek Kumar [3 ]
Dixit, Manish [1 ]
Singh, Uday Pratap [2 ]
Gambhir, Sanjay [1 ]
机构
[1] Sanjay Gandhi Postgrad Inst Med Sci, Dept Nucl Med, Lucknow 226014, Uttar Pradesh, India
[2] Sanjay Gandhi Postgrad Inst Med Sci, Dept Urol, Lucknow, Uttar Pradesh, India
[3] All India Inst Med Sci, Dept Nucl Med, Rishikesh, Uttarakhand, India
来源
INDIAN JOURNAL OF NUCLEAR MEDICINE | 2024年 / 39卷 / 03期
关键词
Ga-68-prostate-specific membrane antigen positron emission tomography; computed tomography; Tc-99m-prostate-specific membrane antigen single photon emission computed tomography; biochemical recurrence; prostate cancer; DEFINITION; SPECT/CT; FAILURE; PSA;
D O I
10.4103/ijnm.ijnm_8_24
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective:Biochemical recurrence (BCR) after initial management of Prostate Carcinoma (PC) is frequent. Subsequent interventions rely on disease burden and metastasis distribution. Ga-68 prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) is an excellent imaging modality in BCR. However, Ga-68 is radionuclide generator produced and has restricted availability. (99)mTc-labeled PSMA could be a potential cost-effective alternative. We compared the performance of Tc-99m-PSMA single-photon emission CT (SPECT)/CT and Ga-68-PSMA PET/CT in BCR with a serum prostate surface antigen (PSA) level of <20 ng/mL. Materials and Methods:The prospective study included 25 patients with BCR and at least one lesion on a Ga-68-PSMA PET/CT. All patients underwent 99 mTc-PSMA SPECT/CT, and disease distribution and metastatic burden were compared with Ga-68-PSMA PET/CT. The maximum standard uptake value (SUVmax) and the tumor-to-background ratio (TBR) were computed and analyzed. Results:The mean age and serum PSA (SPSA) were 69.72 6.69 years and 5.65 +/- 6.07 ng/mL. Eleven patients (44%) had SPSA <= 2 ng/mL. Recurrent sites were noted in the prostate (19, 76%), prostatic bed (3, 12%), and pelvis lymph nodes (LNs) (13, 52%). Distant metastasis to bones (13, 52%), lungs (5, 20%), and retroperitoneal LNs (2, 8%) were noted. Both modalities were concordant for the recurrent disease at the prostate, prostatic bed, bone, and lung lesions. Tc-99m-PSMA could localize pelvis LNs in most patients (10/13, 76.9%). The site-specific sensitivity and specificity between the two modalities were not significantly different (P > 0.05). TBR shows excellent correlation with SUVmax (0.783, P < 0.001). Four (16%) patients were understaged with Tc-99m-PSMA due to the nonvisualization of the subcentimeter size LNs. No patient with systemic metastases was understaged. Conclusions:Tc-99m-PSMA SPECT/CT has good concordance with Ga-68-PSMA PET/CT in BCR, even at low PSA levels. However, it may miss a few subcentimeter LNs due to lower resolution. Tc-99m-PSMA SPECT/CT could be a simple, cost-effective, and readily available imaging alternative to PET/CT.
引用
收藏
页码:170 / 176
页数:7
相关论文
共 50 条
  • [1] Diagnostic sensitivity of Tc-99m HYNIC PSMA SPECT/CT in prostate carcinoma: A comparative analysis with Ga-68 PSMA PET/CT
    Lawal, Ismaheel O.
    Ankrah, Alfred O.
    Mokgoro, Neo P.
    Vorster, Mariza
    Maes, Alex
    Sathekge, Mike M.
    PROSTATE, 2017, 77 (11) : 1205 - 1212
  • [2] INDICATIONS AND RESULTS FOR GA-68 PSMA PET/CT IN PATIENTS WITH BIOCHEMICAL RELAPSE OF PROSTATE CANCER
    Rogic, Ivan
    Golubic, Anja Tea
    Dobrenic, Margareta
    Zuvic, Marijan
    Smitran, Tea
    Jukic, Nino
    Huic, Drazen
    ACTA CLINICA CROATICA, 2024, 63 : 7 - 13
  • [3] Perineum and penile invasion of recurrent prostate carcinoma shown by Ga-68 PSMA PET/CT
    Koc, Zehra Pinar
    Ozcan, Pinar Pelin
    Ercolak, Vehbi
    INDIAN JOURNAL OF CANCER, 2021, 58 (01) : 101 - 103
  • [4] Comparative diagnostic performance of 68Ga-PSMA-11 PET/CT and 68Ga-PSMA-11 PET/MRI in detecting biochemical recurrent bone metastasis in prostate cancer: a systematic review and meta-analysis
    Wen, Xin
    Jiang, Cheng-Yi
    Jiang, Xu
    Chen, Yan
    Li, Meng
    ACTA RADIOLOGICA, 2025, : 312 - 327
  • [5] 68Ga-PSMA-11 PET/CT versus 68Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
    Huang, Ruizhe
    Li, Yizhen
    Wu, Haowen
    Liu, Boyi
    Zhang, Xuanjun
    Zhang, Zhongxi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] 68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: A Prospective, 2-Center Study
    Zacho, Helle D.
    Nielsen, Julie B.
    Dettmann, Katja
    Haberkorn, Uwe
    Langkilde, Niels C.
    Jensen, Jorgen B.
    Petersen, Lars J.
    CLINICAL NUCLEAR MEDICINE, 2018, 43 (08) : 579 - 585
  • [7] The Diagnostic Performance of 68Ga-PSMA-11 PET/MRI for the Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-analysis
    Wang, Dan
    Wang, Zong-Hao
    Wang, Chun-Bao
    Wu, Zhi-Chun
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2024, 53 (06) : 1224 - 1235
  • [8] 99mTc-PSMA SPECT/CT Versus 68Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer
    Fallahi, Babak
    Khademi, Niloufar
    Karamzade-Ziarati, Najme
    Fard-Esfahani, Armaghan
    Emami-Ardekani, Alireza
    Farzanefar, Saeed
    Eftekhari, Mohammad
    Beiki, Davood
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (02) : E68 - E74
  • [9] Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy
    Li, Bo
    Duan, Lili
    Shi, Jingqi
    Han, Yunyun
    Wei, Wei
    Cheng, Xiaoliang
    Cao, Yong
    Kader, Akeban
    Ding, Degang
    Wu, Xinyu
    Gao, Yongju
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] 68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients
    Paola Caroli
    Israel Sandler
    Federica Matteucci
    Ugo De Giorgi
    Licia Uccelli
    Monica Celli
    Flavia Foca
    Domenico Barone
    Antonino Romeo
    Anna Sarnelli
    Giovanni Paganelli
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 2035 - 2044